Abstract
Among the drugs of abuse which are regulated under the United States Controlled Substances Act and the International Conventions, none has created more intense public debate and controversy than marihuana. Marihuana is one of many names given to the leaves and flowering tops of the plant Cannabis sativa. The plant grows in all temperate regions of this planet and has been used commercially as a source of fiber and oil. Wherever the plant grows people have learned to ingest the material for its introxicating effects. The usual routes of administration are by mouth or smoking. It has been estimated that, worldwide, more than one hundred million individuals are regular users of the plant material. However, accurate data on this situation are not available. In the United States, use data have been collected on a regular basis using two large surveys, the National Household Survey on Drug Abuse (SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION 1994) and the Monitoring the Future Survey (JOHNSTON et al. 1994) which covers eighth, tenth, and twelfth grade students in public and private schools. Figure 1 presents the data over time for lifetime, annual, 30 day, and daily use of marihuana among high school seniors in the United States (JOHNSTON et al. 1994). As can be seen, use peaked from 1978 to 1980 and had been declining slowly up to 1992. From 1992 to 1993 there was a significant increase in all use categories. Even more disturbing was the fact that very similar trend data were reported for eighth and tenth graders. This was matched in 1992 and 1993 by a decrease in the reported “perceived risk” from use of the drug.
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Abel EL (1971) Retrieval of information after use of marihuana. Nature 231:58
Abel EL (1985a) Alcohol enhancement of marihuana-induced fetotoxicity. Teratology 31: 35–40
Abel EL (1985b) Effects of prenatal exposure to cannabinoids. In: Pinkert TM (ed) Current research on the consequences of maternal drug abuse. US Government Printing Office, Washington DC, pp 20–35
Abel EL, Dintcheff BA (1986) Increased marihuana-induced fetotoxicity by a low dose of concomitant alcohol administration. J Stud Alcohol 47: 440–443
Abel EL, Schiff BB (1969) Effects of the marihuana homologue, parahexyl, on food and water intake and curiousity in the rat. Psychon Sci 16: 38
Abood ME, Sauss C, Fan F, Tilton CL, Martin BR (1993) Development of behavioral tolerance of Δ9-THC without alteration of cannabinoid receptor binding or mRNA levels in the whole brain. Pharmacol Biochem Behav 46: 575–579
Adams IB, Thomas BF, Compton DR, Razdan RK, Martin BR (in press) Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther
Adams MD, Earnhardt JT, Dewey WL, Harris LS (1976) Vasoconstrictor actions of Δ8- and Δ9-tetrahydrocannabinol in the rat. J Pharmacol Exp Ther 196. 649–656
Adams MD, Earnhardt JT, Martin BR, Harris LS, Dewey WL, Razdan RK (1977) A cannabinoid with cardiovascular activity but no overt bahavioral effects.Experientia 33: 1204–1205
Adams R (1942) Marihuana. Harvey Lect 37: 168–197
Ali SF, Newport GD, Scallet AC, Paule MG, Bailey JR, Slikker W (1991) Chronic marijuana smoke exposure in the rhesus monkey. IV. Neurochemical effects and comparison to acute and chronic exposure to Δ9-tetrahydrocannabinol (THC) in rats. Pharmacol Biochem Behav 40: 677–682
Allebeck P (1993) Schizophrenia and cannabis: cause-effect relationship? In: Nahas GG, Latour C (eds) Cannabis: physiopathology, epidemiology, detection. CRC Press, Boca Raton, pp 113-117
Arata S, Newton C, Klein T, Friedman H (1992) Enhanced growth of Legionella pneumophila in tetrahydrocannabinol-treated macrophages. Proc Soc Exp Biol Med 199: 65–67
Aronow WS, Cassidy J (1975) Effect of smoking marihuana and of a high-nicotine cigarette on angina pectoris. Clin Pharmacol Ther 17 (S): 549–554
Askew WE, Ho BT (1974) The effects of tetrahydrocannabinols on cyclic AMP levels in rat brain areas. Experientia 30: 879–880
Audette CA, Burstein SH, Doyle SA, Hunter SA (1991) G-protein mediation of cannabinoid-induced phospholipase activation. Pharmacol Biochem Behav 40: 559–563
Aussedat M, Niziolek-Reinhardt S (1993) Detection of cannabis and other drugs in 120 victims of road accidents. In: Nahas GG Latour C eds Cannabis: Physiopathology, epidemiology, detection. CRC Press, Boca Raton, pp 73-77
Balster RL, Prescott WR (1992) Δ9-tetrahydrocannabinol discriminination in rats as a model of cannabis intoxication. Neurosci Biobehav Rev 16: 55-62
Barnett C, Chiang C, Perez-Reyes M, Owens S (1982) Kinetic study of smoking marijuana. J Pharmacokinetic Biopharm 10: 495–506
Barnett G, Licko V, Thompson T (1985) Behavioral pharmacokinetics of marijuana. Psychopharmacology 85: 51–56
Bartolucci G, Fryer L, Perris C, Shagass C (1969) Marijuana psychosis: a case report. Can Psychiatr Assoc J 14: 77–79
Beardsley PM, Balster RL, Harris LS (1986) Dependence on tetrahydrocannabinol in rhesus monkeys. J Pharmacol Exp Ther 239: 311–319
Benowitz NL, Rosenberg J, Rogers W, Bachman J, Jones RT (1979) Cardiovascular effects of intravenous Δ9tetrahydrocannabinol: autonomic nervous mechanisms. Clin Pharmacol Ther 25: 440–446
Bhargava HN, (1976) Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice. Psychopharmacology 49: 267–270
Bhargava HN, (1978) Time course of the effects of naturally occurring cannabinoids on morphine abstinence syndrome. Pharmacol Biochem Behav 8: 7–11
Bhattacharya SK, (1986) Δ9-Tetrahydrocannabinol increases brain prostaglandin in the rat. Psychopharmacology 90:499
Bhattacharya Sk, Ghosh P, Sanyal AK (1980) Effects of prostaglandin on some central pharmacological actions cannabis. Indian J Med Res 71: 955–960
Bidaut-Russell M, Howlett A (1988) Opioid and cannabinoid analgetics both inhibit cyclic AMP production in the rat striatum. In: Hamon M, Cros I, Meunier J (eds) Advances in the biosciences: proceedings of the international narcotics research conference. Pergamon, Oxford
Bidaut-Russell M, Howlett AC (1991) Cannabinoid receptor-regulated cyclic AMP accumulation in the rat striatum. J Neurochem 57: 1769–1773
Bloch E (1983) Effects of marihuana and cannabinoids on reproduction, endocrine function, development, and chromosomes. In: Fehr KO, Kalant H (eds) Cannabis and health hazards: proceedings of an ARF/WHO scientific meeting on adverse health and behavioral consequences of cannabis use. Addiction Research Foundation, Toronto, pp 355–432
Bloom AS, Dewey WL (1978) A comparison of some pharmacological actions of morphine and Δ9-tetrahydrocannabinol in the mouse. Psychopharmacology 57: 243–248
Brake SC, Hutchings DE, Morgan B, Lasalle E, Shi T (1987) Delta-9-tetrahydro-cannabinol during pregnancy in the rat: II. Effects on ontogeny of locomotor activity and nipple attachment in the offspring. Neurotoxicol Teratol 9: 45–49
Brostrom MA, Brostrom CO, Breckenridge BM, Wolff DJ (1978) Calcium-dependent regulation of brain adenylate cyclase. Adv Cyclic Nucleotide Res 9: 85–99
Buchanan JF, Davis LJ (1984) Drug-induced infertility. Drug Intell Clin Pharm 18: 122–132
Burstein S (1992) Eicosanoids as mediators of cannabinoid action. In: Murphy L, Bartke A (eds) Marijuana/cannabinoids: neurobiology and Neurophysiology. CRC Press, Boca Raton, pp 73–91
Burstein S, Hunter SA (1981) Prostaglandins and cannabis -VIII. Elevation of phospholipase A2 activity by cannabinoids in whole cells and subcellular preparations. J Clin Pharmacol 21:2405-248S
Burstein S, Raz A (1972) Inhibition of prostaglandin E2 biosynthesis by Δ1-THC. Prostaglandins 2: 369–374
Burstein S, Levin E, Varanelli C (1973) Prostaglandins and cannabis-II: inhibition of biosynthesis by the naturally occuring cannabinoids. Biochem Pharmacol 22: 2905–2910
Burstein S, Varanelli C, Slade LT (1974) Prostaglandins and cannabis-III. Inhibition of biosynthesis by essential oil components of marihuana. Biochem Pharmacol 24: 1053–1054
Burstein SH, Hunter SA, Shoupe TS, Taylor P (1978) Cannabinoid inhibition of testosterone synthesis by mouse Leydig cells. Res Commun Chem Pathol Pharmacol 19: 557–560
Burstein S, Hunter SA, Shoupe TS, (1979) Site of inhibition of leydig cell testosterone synthesis byΔ9-tetrahydrocannabinol. Mol Pharmacol 15: 633–640
Burstein S, Hunter SA, Sedor C (1980) Further studies on the inhibition of Leydig cell testosterone production by cannabinoids. Biochem Pharmacol 29: 2153–2154
Burstein S, Ozman K, Burstein E, Palermo N, Smith E (1982) Prostaglandins and cannabis — XI: inhibition ofΔ1-tetrahydrocannabinol-induced hypotension by aspirin. Biochem Pharmacol 31: 591–592
Burstein S, Hunter SA, Renzulli L (1985) Prostaglandins and cannabis XIV. Tolerance to the stimulatory actions of cannabinoids on arachidonate metabolism. J Pharmacol Exp Ther 235: 87–91
Burstein S, Hunter SA, Latham V, Renzulli L (1987) A major metabolite of Δ1-tetrahydrocannabinol reduces its cataleptic effect in mice. Experientia 43: 402–403
Burstein SH, Hull K, Hunter SA, Shilstone J (1989) Immunization against prostaglandins reduces Δ1-THC-induced catalepsy in mice. Mol Pharmacol 35: 6–9
Burstein SH Audette CA, Charalambous A, Doyle SA, Guo Y, Hunter SA, Makriyannis A (1991) Detection of cannabinoid receptors by Photoaffinity labelling. Biochem Biophys Res Commun 176:492-497
Cabral GA, Vasquez R (1993) Δ9-tetrahydrocannabinol suppresses macrophage extrinsic anti-herpesvirus activity. In: Nahas GG, Latour C (eds) Cannabis: physiopathology, epidemiology, detection. CRC Press, Boca Raton, pp 137-153
Carlini EA, Hamaoui A, Bieniek D, Korte F (1970) Effects of (—) Δ9-trans-tetrahydrocannabinol and a synthetic derivative on maze performance of rats. Pharmacology 4: 359–368
Carney JM, Uwayday IM, Balster RL (1977) Evaluation of a suspension system for intravenous self-administration studies with water-insoluble compounds in the Rhesus monkey. Pharmacol Biochem Behav 7: 357–364
Carney JM, Balster RL, Martin BR, Harris LS (1979) Effects of systemic and intraventricular administration of cannabinoids on schedule-controlled responding in the squirrel monkey. J Pharmacol Exp Ther 210: 399–404
Caulfield MP, Brown DA (1992) Cannabinoid receptor agonists inhibit Ca current in NG108–15 neuroblastoma cells via a Pertussis toxin-sensitive mechanism. Br J Pharmacol 106: 231–232
Cavero I, BuckleY JP, Bhagavan SJ (1973) Hemodynamic and myocardial effects of (—) -Δ9 -trans-tetrahydrocannabinol in anesthetized dogs. Eur J Pharmacol 24: 243–251
Chait LD, Pierri J (1992) Effects of smoked marijuana on human performance: a critical review. In: Murphy L, Bartke A eds Marijuana/cannabinoids: neurobiology and neurophysiology. CRC Press Boca Raton, pp 387–423
Chait LD, Zacny JP (1992) Reinforcing and subjective effects of oral Δ9-THC and smoked marijuana in humans. Psychopharmacology 107: 255–262
Charalambous A, Yan G, Houston DB, Howlett AC, Comton DR, Martin BR, Makriyannis A (1992) 5’ -Azido-Δ8 -THC: A novel Photoaffinity label for cannabinoid receptor. J Med Chem 35:3076-3079
Chaudry A, Thompson RH, Rubin RP, Laychock SG (1988) Relationship between Δ9 -tetrahydrocannabinol-induced arachidonic acid release and secretagogueevoked Phosphoinositide breakdown and Ca 2+ mobilization of exocrine pancreas. Mol Pharmacol 34: 543–548
Chen J, Paredes W, Lowinson JH, Gardner EL (1990) Δ9-Tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur J Pharmacol 190:259-262
Chen J, Marmur R, Pulles A, Paredes W, Gardner E (1993) Ventral to mental microinjection of Δ9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana’s psychoactive ingredient. Brain Res 621: 65–70
Chesher GB, Jackson DM (1985) The quasimorphive withdrawal syndrome: effect of cannabinol cannabidiol and tetrahydrocannabinol. Pharmacol Biochem Behav 23: 13–15
Chesher GB, Dahl CJ, Everingham M, Jackson DM, Merchant-Williams H, Starmer GA (1973) The effect of cannabinoids on intestinal motility and their antinociceptive effect in mice. Br J Pharmacol 49: 588–594
Childers SR, Flemin L, Konko C, Marckel D, Pacheo M, Sexton T, Ward S (1992) Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann NY Acad Sci 654: 33–51
Childers SR, Sexton T, Roy MB (1994) Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem Pharmaco147:711-715
Chkili T, Ktiouet JE (1993) Prospective study of 104 psychiatric cases associated with cannabis use in a Moroccan medical center. In: Nahas GG, Latour C (eds) Cannabis: physiopathology, epidemiology> detection. CRC Press, Boca Raton, pp 101–104
Clapp JFI, Wesley M, Cooke R, Pekala R, Holstein C (1987) The effects of marijuana smoke on gas exchange in ovine pregnancy. Alcohol Drug Res 7: 85–92
Cocchetto D, Owens S, Perez-Reyes M, Di Guiseppi S, Miller L (1981) Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man. Psychopharmacology 75: 158–164
Cohen S, Lessin P, Hahn PM, Tyrell ED (1976) A 94-day cannabis study. In: Braude MC, Szara S (eds) Pharmacology of marihuana. Raven, New York, pp 621–626
Compton DR, Dewey WL, Martin BR (1990a) Cannabis dependence and tolerance production. In: Erickson CK, Javors MA, Morgan WW (eds) Addiction potential of abused drugs and drug classes. Hayworth, Binghampton, pp 129–147
Compton DR, Little PJ, Martin BR, Gilman JW, Saha JK, Jorapur VS, Sard HP, Razdan RK (1990b) Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12- substituted Δ8-tetrahydrocannabinol. J Med Chem 33: 1437–1443
Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR (1992a) Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from Δ9 -tetrahydrocannabinol. J Pharmacol Exp Ther 263: 1118–1126
Compton DR, Johnson MR, Melvin LS, Martin BR (1992b) Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 260: 201–209
Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR, Martin BR (1993) Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265: 218–226
Cone E, Huestis M (1993) Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marihuana usage. Ther Drug Mon 15: 527–532
Cone EJ, Johnson RE, Paul BD, Mell LD, Mitchell J (1988) Marijuana-laced brownies: behavioral effects, physiologic effects, and urinalysis in humans following ingestion. J Anal Toxicol 12: 169–175
Consroe P, Mechoulam R (1987) Anticonvulsant and neurotoxic effects of tetrahydro-cannabinol stereoisomers. In: Rapaka RS, Markiyannis A (eds) Structure-activity relationships of the cannabinoids. US Government Printing Office, Washington DC, pp 59–66
Crawley J, Corwin R, Robinson J, Felder C, Devane W, Axelrod J (1993) Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav 46: 967–972
Dalterio SL (1986) Cannabinoid exposure: effects on development. Neurobehav Toxicol Teratol 8: 345–352
Dalterio S, Bartke A, Harper MJK, Huffman R, Sweeney C (1981) Effects of cannabinoids and female exposure on the pituitary-testicular axis in mice: possible involvement of prostaglandins. Biol Reproduct 24: 315–322
Dalterio S, Steger R, Mayfield D, Bartke A (1984) Early cannabinoid exposure influences neuroendocrine and reproductive functions in male mice: I. Prenatal exposure. Pharmacol Biochem Behav 20: 107–113
Defer B (1993) Cannabis and schizophrenia: how causal a relationship? In: Nahas GG, Latour C (eds) Cannabis: physiopathology, epidemiology, detection. CRC Press, Boca Raton, pp 119–121
Deutsch DG, Chin SA (1993) Enzymatic synthesis and degradation of anadamide, a cannabinoid receptor agonist. Biochem Pharmacol 46: 791–796
Devane W, Axelrod J (1994) Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor by brain membranes. Proc Natl Acad Sci USA 91: 6698–6701
Devane WA, Spain JW, Coscia CJ, Howlett AC (1986) An assessment of the role of opioid receptors in the response to cannabimimetic drugs. J Neurochem 46: 1929–1935
Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605–613
Devane WA, Breuer A, Sheskin T, Järbe TUC, Eisen MS, Mechoulam R (1992a) A novel probe for the cannabinoid receptor. J Med Chem 35: 2065–2069
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992b) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946–1949
Dewey WL (1986) Cannabinoid pharmacology. Pharmacol Rev 38: 151–178
Dewey WL, Jenkins J, Rourke T, Harris LS (1972) The effects of chronic administration of trans- Δ9-tetrahydrocannabinol on behavior and the cardiovascular system. Arch Int Pharmacol Ther 198: 118–131
Dill JA, Howlett AC (1988) Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. J Pharmacol Exp Ther 244: 1157–1163
Dolby TW, Kleinsmith LJ (1974) Effects of Δ9-tetrahydrocannabinol on the levels of cyclic adenosine 3′,5′-monophosphate in mouse brain. Biochem Pharmacol 23: 1817–1825
Dolby TW, Kleinsmith LJ (1977) Cannabinoid effects on adynalate cyclase and phosphodiesterase activities of mouse brain. Can J Physiol Pharmaco155:934-942
Drew WG, Miller LL (1974) Cannabis: neural mechanisms and behavior — a theoretical review. Pharmacology 11: 12–32
Eldridge JC, Landfield PW (1990) Cannabinoid interactions with glucocorticoid receptors in rat hippocampus. Brain Res 534: 135–141
Eldridge JC, Landfield PW (1992) Cannabinoid-glucocorticoid interactions in the hippocampal region of the brain. In: Murphy L, Bartke A (eds) Marijuana/ cannabinoids: neurobiology and neurophysiology. CRC Press, Boca Raton, pp 93–117
ElSohly MA, Ross SA (1994) Quaterly report, NIDA potency monitoring project. Report no 50
Evans D, Lake JT, Johnson MR, Howlett A (1994) Endogenous cannabinoid receptor binding activity released from rat brain slices by depolarization. J Pharmacol Exp Ther 268: 1271–1277
Evans DM, Johnson MR, Howlett AC (1992) Ca2+ -dependent release from rat brain of cannabinoid receptor binding activity. J Neurochem 58: 780–782
Fairbairn JW, Pickens JT (1979) The oral activity of Δ9-tetrahydrocannabinol and its dependence on prostaglandin E2. Br J Pharmacol 67: 379–385
Fairbairn JW, Pickens JT (1980) The effect of conditions influencing endogenous prostaglandins on the activity of Δ9-tetrahydrocannabinol in mice. Br J Pharmacol 69: 491–493
Falkenstein BA, Holley DC (1992) Effect of acute intravenous administration of Δ9-tetrahydrocannabinol on the episodic secretion of immunoassayable growth hormone in the rat. Life Sci 50: 1109–1116
Feigenbaum JJ, Bergmann R, Richmond SA, Mechoulam R, Nadler V, Kloog Y, Sokolovsky M (1989) Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc Natl Acad Sci USA 86: 9584–9587
Felder CC, Veluz JS, Williams HL, Briley EM, Matsuda LA (1992) Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 42: 838–845
Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA (1993) Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 90: 7656–7660
Fernández-Ruiz JJ, de Fonseca FR, Navarro M, Ramos JA (1992) Maternal cannabinoid exposure and brain development: changes in the ontogeny of dopaminergic neurons. In: Murphy L, Bartke A (eds) Marijuana/cannabinoids: neurobiology and neurophysiology. CRC Press, Boca Raton, pp 119-164
Ferraro DP, Grilly DM (1973) Lack of tolerance to Δ9 -tetrahydrocannabinol in chimpanzees. Science 179: 490–492
Ferri S, Costa G, Murari G, Panico AM, Rapisarda E, Speroni E, Arrigo RR (1981) Investigations on behavioral effects of an extract of Cannabis sativa L. in the rat. Psychopharmacology 75: 144–147
Fischer-Stenger K, Updegrove AW, Cabral GA (1992) Δ9-tetrahydrocannabinol decreases cytotoxic T lymphocyte activity to herpes simplex virus type 1-infected cells. Proc Soc Exp Biol Med 200:422-430
Foltin RW, Brady JV, Fischman MW (1986) Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav 25: 577–582
Foltin RW, Fischman MW, Brady JV, Kelly TH, Bernstein DJ, Nellis MJ (1989) Motivational effects of smoked marihuana: behavioral contingencies and high-probability recreational activities. Pharmacol Biochem Behav 34: 871–877
Foltin RW, Fischman MW, Brady JV, Bernstein DJ, Nellis MJ, Kelly TH (1990) Marijuana and behavioral contingencies. Drug Dev Res 20: 67–80
Formukong EA, Evans AT, Evans FJ (1988) Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. Inflammation 12: 361–371
Forney RB, Kiplinger GF (1971) Toxicology and pharmacology of marijuana. Ann NY Acad Sci 191: 74–82
Fraser JD (1949) Withdrawal symptoms in cannabis-indica addicts. Lancet 257: 747–748
Fride E, Mechoulam R (1993) Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 231: 313–314
Fried PA, Makin JE (1987) Neonatal behavioral correlates of prenatal exposure to marihuana, cigarettes and alcohol in a low risk population. Neurotoxicol Teratol 9: 1–7
Gahlinger PM (1984) Gastrointestinal illness and cannabis use in a rural Canadian community. J Psychoactive Drugs 16: 263–265
Gal P, Sharpless MK (1984) Fetal drug exposure-behavioral teratogenesis. Drug Intell Clin Pharm 18: 186–201
Gamse R, Holzer P, Lembeck F (1979) Indirect evidence for presynaptic location of opiate receptors in chemosensitive primary sensory neurones. Arch Pharmacol 308: 281–285
Gardner EL (1992) Cannabinoid interaction with brain reward systems — the neurobiological basis of cannabinoid abuse. In: Murphy L, Bartke A (eds) Marijuana/ cannabinoids: neurobiology and neurophysiology. CRC Press, Boca Raton, pp 275–335
Gardner EL, Lowinson JH (1991) Marijuana’s interaction with brain reward systems — update 1991. Pharmacol Biochem Behav 40: 571–580
Gardner EL, Paredes W, Smith D, Dormer A, Milling C, Cohen A, Morrison D (1988) Facilitation of brain stimulation reward by Δ9-tetrahydrocannabinol. Psychopharmacology 96: 142–144
Gascon AL, Peres MT (1973) Effect of Δ9 - and Δ8 -tetrahydrocannabinol on the peripheral autonomic nervous system in vitro. Can J Physiol Pharmacol 51: 12–21
Gennings C, Carter JWH, Martin BR (1994) Response-surface analysis of morphine sulfate and Δ9 -tetrahydrocannabinol interaction in mice. In: Lange N, Ryan L (eds) Case studies in biometry. Wiley, New York, pp 429–451
George HR (1970) Two psychotic epidodes associated with cannabis. Br J Addict 65: 119–121
Gérard C, Mollereau C, Vassart G, Parmentier M (1990) Nucleotide sequence of a human cannabinoid receptor cDNA. Nucleic Acids Res 18: 7142
Gilbert PE (1981) A comparison of THC, nantradol, nabilone, and morphine in the chronic spinal dog. J Clin Pharmacol 21:311S-319S
Gold L, Balster RL, Barrett RL, Britt DT, Martin BR (1992) A comparison of the discriminative stimulus properties of Δ9 -THC and CP-55 940 in rats and rhesus monkeys. J Pharmacol Exp Ther 262: 479–486
Gough AL, Olley JE (1978) Catalepsy induced by intrastriatal injections of Δ9 -THC and 11-OH-Δ9-THC in the rat. Neuropharmacology 17: 137–144
Greenberg I, Mendelson JH, Kuehnle JC, Mello N, Babor TF (1976) Psychiatric and behavioral observations of casual and heavy marijuana users in a controlled research setting. Ann NY Acad Sci 282: 72–84
Halikas JA, Weller RA, Morse CL, Hoffmann RG (1985) A longitudinal study of marijuana effects. Int J Addict 20: 701–711
Hanus L, Gopher A, Almog S, Mechoulam R (1993) Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 36: 3032–3034
Harclerode J (1984) Endocrine effects of marijuana in the male: preclinical studies. In: Braude MC, Ludford JP (eds) Marijuana effects on the endocrine and reproductive systems. US Government Printing Office, Washington DC, pp 46–64
Harris RA, Stokes JA (1982) Cannabinoids inhibit calcium uptake by brain synaptosomes. J Neurosci 2: 443–447
Harris LS, Pearl J, Aceto MD (1966) Similarities in the effects of barbiturates. Psychonom Sci 4: 267–268
Harris R, Waters W, McLendon D (1974) Evaluation of reinforcing capability of Δ9- tetrahydrocannabinol in rhesus monkeys. Psychopharmacology 37: 23–29
Harris LS, Dewey WL, Razdan RK (1977) Cannabis: its chemistry, pharmacology, and toxicology. In: Martin WR (ed) Drug addiction. Springer, Berlin Heidelberg New York, pp 371-429 (Handbook of experimental pharmacology, vol 45/2)
Harris LS, Carchman RA, Martin BR (1978) Evidence for the existence of specific cannabinoid binding sites. Life Sci 22: 1131–1138
Hatch EE, Bracken MB (1986) Effect of marijuana use in pregnancy on fetal growth. Am J Epidemiol 124: 986–993
Haubrich DR, Ward SJ, Baizman E, Bell MR, Bradford J, Ferrari R, Miller M, Perrone M, Pierson AK, Saelens JK, Luttinger D (1990) Pharmacology of pravadoline: a new analgesic agent. J Pharmacol Exp Ther 255: 511–522
Heindel JJ, Keith WB (1989) Specific inhibition of FSH-stimulated cAMP accumulation by Δ9-tetrahydrocannabinol in cultures of rat Sertoli cells. Toxicol Appl Pharmacol 101: 124–134
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, DeCosta BR, Rice KC (1990) Cannabinoid receptor localization in the brain. Proc Natl Acad Sci USA 87: 1932–1936
Herkenham M, Lynn AB, DeCosta BR, Richfield EK (1991a) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 547: 267–274
Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991b) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563–583
Heyser CJ, Hampson RE, Deadwyler SA (1993) Effects of Δ9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J Pharmacol Exp Ther 264: 294–307
Hillard CJ, Bloom AS (1983) Possible role of prostaglandins in the effects of the cannabinoids on adenylate cyclase activity. Eur J Pharmacol 91: 21–27
Hillard CJ, Pounds JJ, Boyer DR, Bloom AS (1990) Studies of the role of membrane lipid order in the effects of Δ9-tetrahydrocannabinol on adenylate cyclase activation in heart. J Pharmacol Exp Ther 252: 1075–1082
Hiltunen AJ, Jarbe TU, Kamkar MR, Archer T (1989) Behaviour in rats maintained by low differential reinforcement rate: effects of Δ1-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combination. Neuropharmacology 28: 183–189
Hine B (1985) Morphine and Δ9-tetrahydrocannabinol: two-way cross tolerance for antinociceptive and heart rate responses in the rat. Psychopharmacology 87: 34–38
Hine B, Friedman E, Torellio M, Gershon S (1975) Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol. Science 187: 443–445
Hollister LE (1986) Health aspects of cannabis. Pharmacol Rev 38: 1–20
Hollister LE (1988) Marijuana and immunity. J Psychoactive Drugs 20: 3–8
Hollister LE, Gillespie HK, Ohlsson A, Lindgren J-E, Wahlen A, Agurell S (1981) Do plasma concentrations of Δ9-tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharmacol 21:171S-177S
Howes JF, Osgood PF (1976) Cannabinoids and the inhibition of prostaglandin synthesis. In: Nahas GG (ed) Marihuana: chemistry, biochemistry and cellular effects. Springer, Berlin Heidelberg New York, pp 415–424
Howlett AC (1984) Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci 35: 1803–1810
Howlett AC (1985) Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 27: 429–436
Howlett AC (1987) Cannabinoid inhibition of adenylate cyclase: relative activity of constituents and metabolites of marihuana. Neuropharmacology 26: 507–512
Howlett AC, Fleming RM (1984) Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 26: 532–538
Howlett AC, Qualy JM, Khachatrian LL (1986) Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29: 307–313
Howlett AC, Johnson MR, Melvin LS, Milne GM (1988) Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol Pharmacol 33: 297–302
Howlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, Herkenham M (1990a) The cannabinoid receptor: biochemical, anatomical and behavioral characterization. TINS 13: 420–423
Howlett AC, Champion TM, Wilken GH, Mechoulam R (1990b) Stereochemical effects of 11-OH-Δ8 -tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology 29: 161–165
Howlett AC, Evans DM, Houston DB (1992) The cannabinoid receptor. In: Murphy L, Bartke A (eds) Marijuana/cannabinoids: neurobiology and neurophysiology. CRC Press, Boca Raton, pp 35–72
Huestis MA, Henningfield JE, Cone EJ (1992a) Blood Cannabinoids: I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 16: 276–282
Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ (1992b) Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther 52: 31–41
Hunter SA, Audette CA, Burstein S (1991) Elevation of brain prostaglandin E2 levels in rodents by Δ1 -THC. Prostaglandins Leukot Essent Fatty Acids 43: 185
Hutchings DE, Brake SC, Morgan B (1989a) Animal studies of prenatal Δ8 -tetrahydrocannabinol: female embryolethality and effects on somatic and brain growth. Ann NY Acad Sci 562: 133–144
Hutchings DE, Gamagaris Z, Miller N, Fico TA (1989b) The effects of prenatal exposure to Δ9-tetrahydrocannabinol to the rest-activity cycle of the preweanling rat. Neurotoxicol Teratol 11: 353–356
Hutchings DE, Dow-Edwards D 1991 Animal models of opiate, cocaine, and cannabis use. Clin Perinatol 18. 1–22
Iverfeldt K, Ögren SO, Barfai T (1988) Substance P receptors in the rat spinal cord. the effect of GTP and of chronic antidepressant treatment. Acta Physiol Scand 132: 175–179
Jandhyala BS, Buckley JP (1977) Autonomic and cardiovascular effects of chronic Δ9-tetrahydrocannabinol administration in mongrel dogs. Res Commun Chem Pathol Pharmacol 16: 593–607
Jansen EM, Haycock DA, Ward SJ, Seybold VS 1992 Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res 575. 93–102
Järbe TU, Hiltunen AJ (1987) Cannabimimetic activity of cannabinol in rats and pigeons. Neuropharmacol 126: 219–228
Johansson E, Agurell S, Hollister L Halldin M (1988) Prolonged apparent half-life of delta-9-tetrahydrocannabinol in plasma of chronic marijuana users. J Pharm Pharmaco140:374-375
Johson MR, Melvin LS (1986) The discovery of nonclassical cannabinoid analgetics. In: Mechoulam R (ed) Cannabinoids as therapeutic agents. CRC Press, Boca Raton pp 121–144
Johnson V (1988) Adolescent alcohol and marijuana use: a longitudinal assessment of a social learning perspective. Am J Drug Alcohol Abuse 14: 419–439
Johnson V, Pandina RJ (1991) Effects of the family environment on adolescent substance use delinquency, and coping styles. Am J Drug Alcohol Abuse 17: 71–88
Johnston LD O’Malley PM, Bachman JG (1994)National survey results on drug use from the monitoring the future study, 1975-1993, National survey results on drug use from the monitoring the future study, 1975-1993, vol 1 and 2. US Department of Health and Human Services, Washington DC
Jones RT (1971) Marihuana-induced “high”: influence of expectation, setting and previous drug experience. Pharmacol Rev 23: 359–369
Jones RT (1983) Cannabis tolerance and dependence. In: Fehr KO, Kalant H (eds) Cannabis and health hazards. Addiction Research Foundation, Toronto, pp 617-689
Jones RT, Benowitz N (1976) The 30-day trip —clinical studies of cannabis tolerance and dependence. In: Braude MC, Szara S (eds) Pharmacology of marihuana. Raven, New York, pp 627–642
Jones RT, Benowitz N, Bachman J (1976) Clinical studies of cannabis tolerance and dependence. Ann NY Acad Sci 282: 221–239
Jones RT, Benowitz NL, Herning RI (1981) Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 21:143S-1525
Jorapur VS, Khalil ZH, Duffley RP, Razdan RK, Martin BR, Harris LS, Dewey WL (1985) Hashish: Synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of Δ9-tetrahydrocannabinol. J Med Chem 28: 783–787
Kaminski NE, Abood ME, Kessler FK, Martin BR, Schatz AR (1992) Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol 42: 736–742
Kawakami Y, Klein TW, Newton C, Djeu JY, Dennert G, Sector S, Friedman H (1988) Suppression by cannabinoids of a cloned cell line with natural killer cell activity. Proc Soc Exp Biol Med 187: 355–359
Kaymakcalan S (1973) Tolerance to and dependence on cannabis. Bull Narc 25: 39–47
Kaymakcalan S, Deneau GA (1972) Some pharmacologic properties of synthetic Δ9 - tetrahydrocannabinol. Acta Med Turc [Suppl] 1: 5
Kaymakcalan S, Ercan ZS, Turker RK (1975) The evidence of the release of prostaglandin-like material from rabbit kidney and guinea-pig lung by (—) - trans - Δ9 -THC. J Pharm Pharmacol 27: 564–568
Kelly LA, Butcher RW (1973) The effects of Δ1-tetrahydrocannabinol on cyclic AMP levels in WI-38 fibroblasts. Biochim Biophysica Acta 1973: 540–544
Kelly LA, Butcher RW (1979) Effects of Δ1-tetrahydrocannabinol (THC) on cyclic AMP metabolism in cultured human fibroblasts. In: Abood LG, Sharp CW (eds) Membrane mechanisms of drugs of abuse. Liss, New York, pp 227–236
Klein TW, Newton C, Friedman H (1987) Inhibition of natural killer cell function by marijuana components. J Toxicol Environ Health 20: 321–332
Knudsen P, Vilmar T (1984) Cannabis and neuroleptic agents in schizophrenia. Acta Psychiatr Scand 69: 162–174
Kochar MS, Hosko MJ (1973) Electrocardiographic effects of marihuana. J Am Med Assoc 225: 25–27
Koe BK, Milne GM, Weissman A, Johnson MR, Melvin LS (1985) Enhancement of brain [3H]flunitrazepam binding and analgesic activity of synthetic canna-bimimetics. Eur J Pharmacol 109: 201–212
Koutek B, Prestwich GD, Howlett AC, Chin SA, Salehani D, Akhavan N, Deutsch DG (1994) Inhibitors of arachidonyl ethanolamide hydrolysis. J Biol Chem 269: 22937–22940
Kruszka K, Gross R (1994) The ATP- and CoA-independent synthesis of ara-chidonoylethanolamide. J Biol Chem 269: 14345–14348
Kumbaraci NM, Nastuk WL (1980) Effects of Δ9-tetrahydrocannabinol on excitable membranes and neuromuscular transmission. Mol Pharmacol 17: 344–349
Kuster JE, Stevenson JI, Ward SJ, D’Ambra TE, Haycock DA (1993) Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J Pharmacol Exp Ther 264: 1352–1363
Labouvie EW (1990) Personality and alcohol and marihuana use: patterns of convergence in young adulthood. Int J Addict 25: 237–252
Landfield PW, Cadwallader LB, Vinsant S (1988) Quantitative changes in hippocampal structure following long-term exposure to Δ9-tetrahydrocannabinol: possible mediation by glucocorticoid systems. Brain Res 443: 47
Layman JM (1971) Some actions of Δ1-tetrahydrocannabinol and cannabidiol at cholinergic junctions. Proc Br Pharmacol Soc 41: 379 p
Leader JP, Koe BK, Weisman A (1981) GABA-like actions of levonantradol. J Clin Pharmacol 21: 2625–2705
Leirer VO, Yesavage JA, Morrow DG (1991) Marijuana carry-over effects on aircraft pilot performance. Aviat Space Environ Med 62: 221–227
Leirer VO, Yesavage JA, Morrow DG (1993) Marijuana carry-over effects on psychomotor performance: a chronicle of research. In: Nahas GG, Latour C (eds) Cannabis: physiopathology, epidemiology, detection. CRC Press, Boca Raton, pp 47–60
Lemberger L, Crabtree RE, Rowe HM (1972a) 11-Hydroxy-9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science 177:62-64
Lemberger L, Weiss JL, Watanabe AM, Galanter IM, Wyatt RJ, Cardon PV (1972b) Δ9-Tetrahydrocannabinol: temporal correlation of the psychologic effects and blood levels after various routes of administration. N Eng J Med 286:685-688
Lemberger L, McMahon R, Archer R, Matsumoto K, Rowe H (1974) Pharmacologic effects and physiologic disposition of delta 6a, 10a dimethylheptyl tetrahydrocannabinol (DMHP) in man. Clin Pharmacol Ther 15: 380–386
Li DMF, Ng CKM (1984) Effects of Δ1- and Δ6-tetrahydrocannabinol on the adynalate cyclase activity in ventricular tissue of the rat heart. Clin Exp Pharmacol Physiol 11: 81–85
Lichtman AH, Martin BR (1991) Spinal and supraspinal mechanisms of cannabinoid-induced antinociception. J Pharmacol Exp Ther 258: 517–523
Lichtman AH, Dimen KR, Martin BR (1995) Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology 119: 282–290
Lindgren J, Ohlsson A, Agurell S, Hollister L, Gillesie H (1981) Clinical effects and plasma levels of delta-9-tetrahydrocannabinol in heavy and light users of cannabis. Psychopharmacology 74: 208–212
Linton PH Kuechenmeister CA, White HB, Travis RP 1975 Marijuana: heartrate and EEG response. Res Commun Chem Pathol Pharmaco1 10. 201–214
Little PJ Martin BR (1991) The effects of Δ9-tetrahydrocannabinol and other cannabinoids on cAMP accumulation in synaptosomes. Life Sci 48: 1133–1141
Little PJ, Kaplan NC, Martin BR (1987) Pharmacological Profile of Δ9-THC carbamate. Alcohol Drug Res 7: 517–523
Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR (1988) Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther 247: 1046–1051
Little PJ,Compton DR, Mechoulam R, Martin BR (1989) Stereochemical effects of 11-OH-dimethylheptyl-Δ8 -tetrahydrocannabinol. Pharmacol Biochem Behav 32: 661–666
Loewe S (1946) The rate of disappearance of marihuana-active substance from the circulating blood. J Pharmacol Exp Ther 294-296
Lynn A, Herkenham M (1994) Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat. implications for receptor-mediated immune modulation by cannabinoids.J PharmacolExp Ther 268: 1612–1623
Mackie K, Hille B (1992) Cannabinoids inhibit N-type calcium channels in neurobalstoma-glioma cells. Proc Natl Acad Sci USA 89: 3825–3829
Mackie K, Devane W, Hille B (1993) Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neurblastoma cells. Mol Pharmacol 44: 498–503
Mailleux P, Vanderhaeghen J (1993a) Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J Neurochem 61: 1705–1712
Mailleux P, Vanderhaeghen JJ (1993b) Glucocorticoid regulation of cannabinoid receptor messenger RNA levels in the rat caudate-putamen. An in situ hydridization study. Neurosci Lett 156: 51–53
Malit LA, Johnstone RE, Bourke DI, Kulp RA, Klein V, Smith TC (1975) Intravenous Δ9-tetrahydrocannabinol: effects on ventilatory control and cardiovascular dynamics. Anesthesiology 42: 666–673
Malit LA, Johnstone RE, Bourke DI, Kulp RA, Klein V, Smith TC (1975) Intravenous Δ9-tetrahydrocannabinol: effects on ventilatory control and cardiovascular dynamics. Anesthesiology 42: 666–673
Margulies JE, Hammer RP (1991) Δ9-tetrahydrocannabinol alters cerebral metabolism in a bi hasic dose-dependent manner in rat brain. Eur J Pharmacol 202:373-378
Martin BR (1985a) Characterization of the antinociceptive activity of intravenously administered Δ9 -tetrahydrocannabinol in mice. In: Harvey DJ (ed) Marihuana’84 proceedings of the oxford symposium on cannabis. IRL Press Oxford, pp 685–692
Martin BR (1985b) Structural requirements for cannabinoid-induced antinociceptive activity in mice. Life Sci 36: 1523–1530
Martin BR (1986) Cellular effects of cannabinoids. Pharmacol Rev 38: 45–74
Martin BR, Dewey WL, Harris LS, Beckner JS (1976)3H-Δ9 -tetrahydrocannabinol tissue and subcellular distribution in the central nervous system and distribution in peripheral organs of tolerant and nontolerant dogs. J Pharmacol Exp Ther 196:128-144
Martin BR, Kallman MJ, Kaempf GF, Harris LS, Dewey WL, Razdan RK (1984) Pharmacological potency of R- and S-3′ -hydroxy-Δ9-tetrahydrocannabinol: additional structural requirement for cannabinoid activity. Pharmacol Biochem Behav 21: 61–65
Martin BR, Compton DR, Little PJ, Martin TJ, Beardsley PM (1987) Pharmacological evaluation of agonistic and antagonistic activity of cannabinoids. In: Rapaka RS, Makriyannis A (eds) Structure-activity relationships of cannabinoids. US Government Printing Office, Washington DC, pp 108–122
Martin BR, Howlett AS, Welch SP (1989) Cannabinoid action in the central nervous system. In: Harris LS (ed) Problems of drug dependence 1988. Proceedings of the 50th annual scientific meeting. US Government Printing Office, Washington DC, 275-283
Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R, Ward SJ (1991) Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40: 471–478
Martin BR, Welch SP, Abood M (1994) Progress toward understanding the cannabinoid receptor and its second messenger systems. In: August JT, Anders MW, Murad F (eds) Advances in pharmacology. Academic, San Diego, pp 341–397
Martin WJ, Lai NK, Patrick SL, Tsou K, Walker JM (1993) Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res 629: 300–304
Mason AP, McBay AJ (1984) Ethanol, marijuana, and other drug use in 600 drivers killed in single-vehicle crashes in North Carolina, 1978–1981. J Forensic Sci 29: 987–1026
Mason AP, McBay AJ (1985) Cannabis: pharmacology and interpretation of effects. J Forensic Sci 30: 615–631
Mathew RJ, Wilson WH (1992) The effects of marijuana on cerebral blood flow and metabolism. In: Murphy L, Bartke A (eds) Maijuana/cannabinoids: neurobiology and neurophysiology. CRC Press, Boca Raton, pp 337–386
Mathew RJ, Wilson WH (1993) Acute changes in cerebral blood flow after smoking marijuana. Life Sci 52: 757–767
Mathew RJ, Wilson WH, Humphreys DF, Lowe JV, Wiethe KE (1992) Regional cerebral blood flow after marijuana smoking. J Cereb Blood Flow Metab 12: 750–758
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned dDNA. Nature 346: 561–564
Maykut MO (1984) Health consequences of acute and chronic marihuana use, health consequences of acute and chronic marihuana use. Pergamon, Oxford
McBay A (1986) Drug concentrations and traffic safety. Adv Alcohol Subst Abuse 2: 51–59
McMillan DE, Dewey WL (1972) On the mechanism of tolerance to Δ9-THC. In: Lewis MF (ed) Current research in marihuana. Academic, New York, pp 97–128
McMillan DE, Harris LS, Frankenheim JM, Kennedy JS (1970) L-Δ9-trans-tetrahydrocannabinol in pigeons: tolerance to the behavioral effects. Science 169: 501–503
McMillan DE, Dewey WL, Harris LS (1971) Characteristics of tetrahydrocannabinol tolerance. Ann NY Acad Sci 191: 83–99
Mechoulam R, Lander N, Srebnik M, Zamir, I, Breuer A, Shalita B, Dikstein S, Carlini EA, Leite JR, Edery H, Porath G (1984) Recent advances in the use of cannabinoids as therapeutic agents. In: Agurell S, Dewey W, Willette (eds) The cannabinoids: chemical, pharmacologic and therapeutic aspects. Academic, New York, pp 777–793
Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Jarbe TUC, Hiltunen AJ, Consroe P (1988) Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 44: 762–764
Mechoulam R, Hanus L, Ben-Shabat S, Fride E, Weidenfeld J (1994) The anandamides, a family of endogenous cannabinoid ligands - chemical and biological studies. Neuropsychopharmacology 10:145S-145S
Mellors A (1979) Cannabinoids and membrane-bound enzymes. In: Nahas GG, Paton WDIVI (eds) Marihuana biological effects-analysis, metabolsim, cellular responses, reproduction and brain. Pergamon, Oxford, pp 329–342
Melvin LS, Johnson MR, Harbert CA, Milne GM, Weissman A (1984) A cannabinoid derived prototypical analgesic. J Med Chem 27: 67–71
Mendelson JH, Babor TF, Kuehenle JC, Rossi AM, Berstein JG, Mello NK, Greenberg I (1976) Behavioral biologic aspects of marihuana use. Ann NY Acad Sci 282: 186–210
Meyer RE (1978) Behavioral pharmacology of marihuana. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven, New York, pp 1639–1652
Miczek KA, Dihit BN (1980) Behavioral and biochemical effects of chronic Δ9-tetrahyrocannabinol in rats. Psychopharmacology 67: 195–202
Molnar J, Petri I, Berek I, Shoyama Y, Nishioka I (1987) The effects of cannabinoids and cannabispiro compounds on Escherichia coli adhesion to tissue culture cells and on leukocyte functions in vitro. Acta Microbiol Hung 34: 233–240
Morgan B, Brake SC, Hutchings DE, Miller N, Gamagaris Z (1988) Δ9-tetrahydro-cannabinol during pregnancy in the rat: effects on development of RNA, DNA, and protein in offspring brain. Pharmacol Biochem Behav 31:365-369
Moskowitz H (1985) Marihuana and driving. Accid Anal Prevent 17: 323–345
Mountjoy KG, Robbins LS, Mortrud MT, Cone RD (1992) The cloning of a family of genes that encode the melanocortin receptors. Science 257: 1248–1251
Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61–64
Munson AE, Fehr KO (1983) Immunological effects of cannabis. In: Fehr KO, Kalant H (eds) Cannabis and health hazards: proceedings of an ARF/WHO scientific meeting on adverse health and behavioral consequences of cannabis use. Addiction Research Foundation, Toronto, pp 257–354
Murphy LL, Newton SC, Dhali J, Chavez D (1991) Evidence for a direct anterior pituitary site of Δ9-tetrahydrocannabinol action. Pharmacol Biochem Behav 40: 603–607
Nahas G (1993a) General toxicity of cannabis. In: Nahas GG, Latour C (eds) Cannabis: physiopathology, epidemiology, detection. CRC Press, Boca Raton, pp 5–17
Nahas G (1993b) Historical outlook of the psychopathology of cannabis. In: Nahas GG, Latour C (eds) Cannabis: physiopathology, epidemiology, detection. CRC Press, Boca Raton, pp 95–99
Nahas G, Latour C (1992) The human toxicity of marijuana. Med J Aust 156: 495–497
Nakamura EM, Da Silva EA, Concilio GV, Wilkinson DA, Masur J (1991) Reversible effects of acute and lot-term administration of Δ9-tetrahydrocannabinol (THC) on memory in the rat. Drug Alcohol Depend 28: 167–175
Nakano Y, Pross SH, Friedman H (1992) Modulation of interleukin 2 activity by Δ9 -tetrahydrocannabinol after stimulation with concanavalin A, phytohemagglutinin, or anti-CD3 antibody. Proc Soc Exp Biol Med 201: 165–168
Nakano Y, Pross S, Friedman H (1993) Contrasting effect of Δ9-tetrahydrocannabinol on IL-2 activity in spleen and lymph node cells of mice of different ages. Life Sci 52: 41–51
Naor Z (1990) Cyclic GMP stimulates inostitol phosphate production in cultured pituitary cells: Possible implications to signal transduction. Biochem Biophys Res Commun 167: 982–992
Narimatsu S, Watanabe K, Yamamoto I, Yoshimura H (1988) Mechanism for inhibitory effect of cannabidiol on microsomal testosterone oxidation in male rat liver. Drug Metab Dispos 16: 880–889
Navarro M, Fernandez-Ruiz JJ, De Miguel R, Hernandez ML, Cebeira M, Ramos JA (1993) Motor disturbances induced by an acute dose of Δ9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations. Pharmacol Biochem Behav 45: 291–298
Negrete JC (1993) Effects of cannabis on schizophrenia. In: Nahas GG, Latour C (eds) Cannabis: physiopathology, epidemiology, detection. CRC Press, Boca Raton, pp 105–112
Newman LM, Lutz MP, Gould MH, Domino EF (1974) Δ9-tetrahydrocannabinol and ethyl alcohol: evidence for cross-tolerance in the rat. Science 175:1022-1023
Niemi WD (1979) Effect of Δ9 -tetrahydrocannabinol on synaptic transmission in the electric eel electroplaque. Res Commun Chem Pathol Pharmacol 25: 537–546
Nishizuka Y (1983) Calcium, phospholipid turnover and transmembrane signalling. Philos Trans R Soc Lond 302: 101–112
Nishizuka Y (1984) The role of protein kinase C in cell surface signal transduction and tumour promotion: Nature 308: 693–697
Nowicky AV, Teyloer TJ, Vardaris RM (1987) The modulation of long-term potentiation by Δ9-tetrahydrocannabinol in the rat hippocampus, in vitro. Brain Res Bull 19: 663–672
Noyes JR, Brunk SF, Avery DH, Canter A (1975) The analgesic properties of Δ9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 18: 84–89
Nye JS, Seltzman HH, Pitt CG, Snyder SH (1984) Labelling of a cannabinoid binding site in brain with a [3H]quarternary ammonium analogue of Δ8-THC. In: Harvey DJ (ed) Marijuana’84: proceedings of the oxford symposium on cannabis. IRL Press, Oxford, pp 253–262
Nye JS, Seltzman HH, Pitt CG, Snyder SS (1985) High-affinity cannabinoid binding sites in brain membranes labeled with [3H]-5′-trimethylammonium-Δ8-tetra-hydrocannabinol. J Pharmacol Exp Ther 234: 784–791
O’Connell CM, Fried PA (1984) An investigation of prenatal cannabis exposure and minor physical anomalies in a low risk population. Neurobehav Toxicol Teratol 6: 345–350
O’Connell CM, Fried PA (1991) Prenatal exposure to cannabis: a preliminary report of postnatal consequences in school-age children. Neurotoxicol Teratol 13: 631–639
Ohlsson A, Lindgren J-E, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1980) Plasma Δ9-tetrahydrocannabinol concentrations and effect after oral and intra-venous administration and smoking. Clin Pharmacol Ther 28: 409–416
Ohlsson A, Lindgren J-E, Wahlen A, Agurell, S, Hollister L, Gillespie H (1982) Single dose kinetics of deuterium labelled Δ1-tetrahydrocannabinol in heavy and light cannabis users. Biomed Mass Spectrom 9: 6–11
Ohlsson A, Agurell S, Londgren J, Gillespie H, Hollister L (1985) Pharmacokinetics studies of delta-1-tetra hydrocannabinol in man. In: Barnett G, Chiang C (eds) Pharmacokinetics and pharmacodynamics of psychoactive drugs. Biomedical, Stony Brook, pp 75–92
Okada M, Mine K, Fujiwara M (1989) Relationship of calcium and adenylate cyclase messenger systems in rat brain synaptosomes. Brain Res 501: 23–31
Okada M, Urae A, Mine K, Shoyama Y, Iwasaki K, Fujiwara M (1992) The facilitating and suppressing effects of Δ9-tetrahydrocannabinol on the rise in intrasynaptosomal Ca 2+ concentration in rats. Neurosci Lett 140: 55–58
Olson KG, Welch SP (1991) The effects of dynorphin A (1–13) and U50 488H on free intracellular calcium in guinea pig cerebellum. Life Sci 48: 575–581
Onaivi ES, Green MR, Martin BR (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253: 1002–1009
Oviedo A, Glowa J, Herkenham M (1993) Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 616: 293–302
Pacheco M, Childers SR, Arnold R, Casiano F, Ward SJ (1991) Aminoalkylindoles: actions on specific G-protein-linked receptors. J Pharmacol Exp Ther 257: 170-183
Pacheco M, Ward S, Childers S (1994) Differential requirements of sodium for coupling of cannabinoid receptors to adenylyl cyclase in rat brain membranes. J Neurochem 62: 1773–1782
Page JB (1983) The amotivational syndrome hypothesis and the Costa Rica study: relationships between methods and results. J Psychoactive Drugs 15: 261–267
Paria BC, Kapur S, Dey SK (1992) Effects of 9-ene-tetrahydrocannabinol on uterine estrogenicity in the mouse. J Steroid Biochem Mol Biol 42: 713–719
Paule MG, Allen RR, Bailey JR, Scallet AC, Ali SF, Brown RM, Slikker W (1992) Chronic marijuana smoke exposure in the rhesus monkey II: effects on progressive ratio and conditioned position responding. J Pharmacol Exp Ther 260: 210–222
Perez-Reyes M (1985) Pharmacodynamics of certain drugs of abuse. In: Barnett G, Chiang C (eds) Pharmacokinetics and pharmacodynamics of psychoactive drugs. Biomedical Publications, pp 287–310
Perez-Reyes M, Owens S, Di Guiseppi S (1981) The clinical pharmacology and dynamics of marijuana cigarette smoking. J Clin Pharmacol 21:201S-207S
Perez-Reyes M, Di Guiseppi S, Davis KH, Schindler VH, C.E. C (1982) Comparison of effects of marihuana cigarettes of three different potencies. Clin Pharmacol Ther 31: 617–624
Perez-Reyes M, Burstein SH, White WR, McDonald SA, Hicks RE (1991) Antagonism of marihuana effects by indomethacin in humans. Life Sci 48: 507–515
Pertwee RG (1972) The ring test: a quantitative method for assessing the “cataleptic” effect of cannabis in mice. Br J Pharmacol 46: 753–763
Pertwee RG (1988) The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 36: 189–261
Pertwee (1990) The central neuropharmacology of psychotropic cannabinoids. In: Balfour DJK (ed) Psychotropic drugs of abuse. Pergamon, New York, p 355
Pertwee R (1992) In vivo interactions between psychotropic cannabinoids and other drugs involving central and peripheral neurochemical mediators. In: Murphy L, Bartke A (eds) Marihuana /cannabinoids: neurobiology and neurophysiology. CRC Press, Boca Raton, pp 165–218
Pertwee RG, Wickens AP (1991) Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology 30: 237–244
Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG (1991) Recent clinical experience with dronabinol. Pharmacol Biochem Behav 40: 695–700
Poklis A, Maginn D, Barr JL (1987) Drug findings in “driving under the influence of drugs” cases: a problem of illicit drug use. Drug Alcohol Depend 20: 57–62
Pradhan SN (1984) Pharmacology of some synthetic tetrahydrocannabinols. Neurosci Biobehav Rev 8: 369–385
Pross S, Nakano Y, Smith J, Widen R, Rodriguez A, Newton C, Friedman H (1992a) Suppressive effect of tetrahydrocannabinol on specific T cell subpo-pulations in the thymus. Thymus 19: 97–104
Pross SH, Nakano Y, McHugh S, Widen R, Klein TW, Friedman H (1992b) Contrasting effects of THC on adult murine lymph node and spleen cell populations stimulated with mitogen or anti-CD3 antibody. Immunopharmacol Immunotoxicol 14: 675–687
Pross SH, Nakano Y, Widen R, McHugh S, Newton CA, Klein TW, Friedman H (1992c) Differing effects of Δ9-tetrahydrocannabinol (THC) on murine spleen cell populations dependent upon stimulators. Int J Immunopharmacol 14: 1019–1027
Purohit V, Ahluwahlia BS, Vigersky RA (1980) Marihuana inhibits dihydrotestosterone binding to the androgen receptor. Endocrinology 107: 848–850
Raffel G, Clarenbach P, Peskar BA, Hertting G (1976) Synthesis and release of prostaglandins by rat brain synaptosomal fractions. J Neurochem 26: 493–498
Razdan RK (1986) Structure-activity relationships in cannabinoids. Pharmacol Rev 38: 75–149
Reggio PH, Seltzman HH, Compton DR, Prescott WR, Martin BR (1990) An investigation of the role of the phenolic hydroxyl in cannabinoid activity. Mol Pharmacol 38: 854–862
Reggio PH, McGaughey GB, Odear DF, Seltzman HH, Compton DR, Martin BR (1991) A rational search for the separation of psychoactivity and analgesia in cannabinoids. Pharmacol Biochem Behav 40: 479–486
Reggio PH, Panu AM, Miles S (1993) Characterization of a region of steric interference at the cannabinoid receptor using the active analog approach. J Med Chem 36: 1761–1771
Reichman M, Nen W, Hokin LE (1987) Effects of Δ9-tetrahydrocannabinol on prostaglandin formation in brain. Mol Pharmacol 32: 686–690
Reuter H (1983) Calcium channel modulation by neurotransmitters, enzymes and drugs. Nature 301: 569–574
Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié P, Brelière JC, Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240–244
Rodriguez de Fonseca F, Cebeira M, Fernandez RJJ, Navarro M, Ramos JA (1991a) Effects of pre- and perinatal exposure to hashish extracts on the ontogeny of brain dopaminergic neurons. Neuroscience 43: 713–723
Rodriguez de Fonseca F, Fernandez RJJ, Murphy L, Eldridge JC, Steger RW, Bartke A (1991b) Effects of Δ9-tetrahydrocannabinol exposure on adrenal medullary function: evidence of an acute effect and development of tolerance in chronic treatments. Pharmacol Biochem Behav 40: 593–598
Rodriguez de Fonseca F, Fernández-Ruiz JJ, Murphy LL, Cebeira M, Steger RW, Bartke A, Ramos JA (1992a) Acute effects of Δ9-tetrahydrocannabinol on dopaminergic activity in several rat brain areas. Pharmacol Biochem Behav 42:269-275
Rodriguez de Fonseca F, Hernandez ML, de MR, Fernandez RJJ, Ramos JA (1992b) Early changes in the development of dopaminergic neurotransmission after maternal exposure to cannabinoids. Pharmacol Biochem Behav 41: 469–474
Rodriguez de Fonseca F, Ramos JA, Bonnin A, Fernandez RJJ (1993) Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 4: 135–138
Rodriguez de Fonseca F, Gorriti M, Fernandez RJJ, Palomo T, Ramos JA (1994) Downregulation of rat brain cannabinoid binding sites after chronic Δ9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav 47: 33–40
Rosell S, Agurell S, Martin B (1976) Effects of cannabinoids on isolated smooth muscle preparations. In: Nahas GG (ed) Marihuana: chemistry, biochemistry, and cellular effects. Springer, Berlin Heidelberg New York, pp 397–406
Rosell S, Bjorkroth U, Agurell S, Leander K, Ohlsson A, Martin B, Mechoulam R (1979) Relation between effects of cannabinoid derivatives on the twitch response of the isolated guinea-pig ileum and their psychotropic properties. In: Nahas GG, Paton WDM (eds) Marihuana biological effects-analysis, metabolism, cellular responses, reproduction and brain. Pergamon, Oxford, pp 63–70
Rosenkrantz H (1983) Cannabis, marihuana, and cannabinoid toxicological manifestations in man and animals. In: Fehr KO, Kalant H (eds) Cannabis and health hazards: proceedings of an ARF/WHO scientific meeting on adverse health and behavioral consequences of cannabis use. Addiction Research Foundation, Toronto, pp 91–176
Rosenkrantz H (1985) Cannabis components and responses of neuroendocrine-reproductive targets: An overview. In: Paton W, Nahas GG (eds) Marihuana’84: proceedings of the Oxford symposium on cannabis. IRL Press, Oxford, pp 457–505
Rosenkrantz H, Grant RJ, Fleischman RW, Barker JR (1986) Marihuana-induced embryotoxicity in the rabbit. Fund Appl Toxicol 7: 236–243
Roth SH, Williams PJ (1979) The non-specific membrane binding properties of Δ9- tetrahydrocannabinol and the effects of various solubilizers. J Pharm Pharmacol 31: 224–230
Rupniak NM, Samson NA, Steventon MJ, Iversen SD (1991) Induction of cognitive impairment by scopolamine and noncholinergic agents in rhesus monkeys. Life Sci 48: 893–899
Sanders J, Jackson DM, Starmer GA (1979) Interactions among the cannabinoids in the antagonism of abdominal constriction response in the mouse. Psychopharmacology 61: 281–285
Scallet AC (1991) Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol Biochem Behav 40: 671–676
Scallet AC, Uemura E, Andrews A, Ali SF, McMillan DE, Paule MG, Brown RM, Slikker W (1987) Morphometric studies of the rat hippocampus following chronic Δ9-tetrahydrocannabinol (THC). Brain Res 436: 193–198
Schwartz RH (1993) Chronic marihuana smoking and short-term memory impairment. In: Nahas GG, Latour C (eds) Cannabis: physiopathology, epidemiology, detection. CRC Press, Boca Raton, pp 61–71
Schwartz RH, Hoffmann NG, Jones R (1987) Behavioral, psychosocial, and academic correlates of marijuana usage in adolescence. A study of a cohort under treatment. Clin Pediatr (Phila) 26: 264–270
Semus SF, Martin BR (1990) A computergraphic investigation into the pharmacological role of the THC-cannabinoid phenolic moiety. Life Sci 46: 1781–1785
Shook JE, Burks TF (1989) Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 249: 444–449
Slikker W Jr, Paule MG, Ali SF, Scallet AC, Bailey JR (1992) Behavioral, neurochemical, and neurohistological effects of chronic marijuana smoke exposure in the nonhuman primate. In: Murphy L, Bartke A (eds) Marijuana/cannabinoids: neurobiology and neurophysiology. CRC Press, Boca Raton, pp 219–273
Smiley KA, Karler R, Turkanis SA (1976) Effects of cannabinoids on the perfused rat heart. Res Commun Chem Pathol Pharmacol 14: 659–675
Smith PB, Martin BR (1992) Spinal mechanisms of Δ9-tetrahydrocannabinol-induced analgesia. Brain Res 578: 8–12
Smith PB, Welch SP, Martin BR (1993) nor-Binaltorphimine specifically inhibits Δ9-tetrahydrocannabinol-induced antinociception in mice without altering other pharmacological effects. J Pharmacol Exp Ther
Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270: 219–227
Soderstrom CA, Trifillis AL, Shankar BS, Clark WE, Cowley A (1993) Marijuana and alcohol use among 1023 trauma patients. In: Nahas GG, Latour C (eds) Cannabis: physiopathology, epidemiology, detection. CRC Press, Boca Raton, pp 79–92
Sofia RD, Barry H (1974) Acute and chronic effects of Δ9-tetrahydrocannabinol on food intake by rats. Psychopharmacology 39: 213–222
Sofia RD, Nalepa SD, Harakal JJ, Vassar HB (1973) Anti-edema and analgesic properties of Δ9-tetrahydrocannabinol (THC). J Pharmacol Exp Ther 186: 646–655
Solomons K, Neppe VM (1989) Cannabis — its clinical effects. S Afr Med J 76: 102–104
Soueif MI (1976) Cannabis-type dependence: the psychology of chronic heavy consumption. Ann NY Acad Sci 282: 121–125
Specter SC, Klein TW, Newton C, Mondragon M, Widen R, Friedman H (1986) Marijuana effects on immunity: suppression of human natural killer cell activity of Δ9-tetrahydrocannabinol. Int J Immunopharmacol 8: 741–745
Spronck HJW, Luteijn JM, Salemink CA, Nugteren DH (1978) Inhibition of prostaglandin biosynthesis by derivatives of olivetol formed under pyrolysis of cannabidiol. Biochem Pharmacol 27: 607–608
Substance Abuse and Mental Health Services Administration (1994) Preliminary estimates from the 1993 National Household Survey on Drug Abuse. US Department of Health and Human Services, Washington DC (Advance report no 7)
Talbott JA, Teague JW (1969) Marihuana Psychosis. JAMA 210: 299–302
Tang JL, Lancz G, Specter S, Bullock H (1992) Marijuana and immunity: tetrahydrocannabinol-mediated inhibition of growth and phagocytic activity of the murine macrophage cell line, P388D1. Int J Immunopharmacol 14: 253–262
Taschner KL (1983) Psychopathology and differential diagnosis of so-called Cannabis psychoses. Fortschr Neurol Psychiatr 51: 235–248
Tennant FS (1983) Clinical toxicology of cannabis use. In: Fehr KO, Kalant H (eds) Cannabis and health hazards: proceedings of an ARF/WHO scientific meeting on adverse health and behavioral consequences of cannabis use. Addiction Research Foundation, Toronto, pp 69–90
Tennes K, Avitable N, Blackard C, Boyles C, Hassoun B, Holmes L, Kreye M (1985) Marijuana: prenatal and postnatal exposure in the human. In: Pinkert TM (ed) Current research on the consequences of maternal drug abuse. US Government Printing Office, Washington DC, pp 48–60
Thomas BF, Compton DR, Martin BF, Semus SF (1991) Modeling the cannabinoid receptor: a three-dimensional quantitative structure-activity analysis. Mol Pharmacol 40: 656–665
Thomas BF, Wei X, Martin BR (1992) Characterization and autoradiographic localization of the cannabinoid binding site in rat brain using [3H] 11-OH-Δ9-THC-DMH. J Pharmacol Exp ther 263: 1383–1390
Thornicroft G (1990) Cannabis and psychosis: is there epidemiological evidence for an association? Br J Psychiatry 157: 25–33
Tramposch A, Sangdee C, Franz DN, Karler R, Turkanis SA (1981) Cannabinoid-induced enhancement and depression of cat monosynaptic reflexes. Neuropharmacology 20: 617–621
Tuchmann-Duplessis H (1993) Effects of cannabis on reproduction. In: Nahas GG, Latour C (eds) Cannabis: physiopathology, epidemiology, detection. CRC Press, Boca Raton, pp 187–192
Tulunay FC, Ayhan IH, Portoghese PS, Takemori AE (1981) Antagonism by chlornaltrexamine of some effects of Δ9-tetrahydrocannabinol in rats. Eur J Pharmacol 70: 219–224
Tulunay FC, Ayhan IH, Sparber SB (1982) The effects of morphine and Δ9-tetra-hydrocannabinol on motor activity in rats. Psychopharmacology 78: 358–360
Tunving K (1987) Psychiatric aspects of cannabis use in adolescents and young adults. Pediatrician 14: 83–91
Turkanis SA, Karler R (1986) Effects of Δ9-tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol and cannabidiol on neuromuscular transmission in the frog. Neuropharmacology 25: 1273–1278
Turker RK, Kaymakcalan S, Ercan ZS (1975) Antihistaminic action of (—)-trans-Δ9-tetrahydrocannabinol. Arch Int Pharmacodyn Ther 214: 254–262
Tyrey L (1984) Endocrine aspects of cannabinoid action in female subprimates: search for sites of action. In: Braude MC, Ludfor JP (eds) Marijuana effects on the endocrine and reproductive systems. US Government Printing Office, Washington DC, pp 65–81
Tyrey L (1992) Δ9-tetrahydrocannabinol attenuates luteinizing hormone release induced by electrochemical stimulation of the medial preoptic area. Biol Reprod 47:262-267
Uphouse LA, Welch SP, Ellis EF, Embrey JP (1993) Antinociceptive activity of intrathecal ketoralac is blocked by the kappa-opioid antagonist, nor-binaltor-phimine. Eur J Pharmacol 242: 53–58
Van der Kloot W (1994) Anandamide, a naturally-occurring agonist of the cannabinoid receptor, blocks adenylate cyclase at the frog neuromuscular junction. Brain Res 649: 181–184
Vaysse PJ, Gardner EL, Zukin RS (1987) Modulation of rat brain opioid receptors by cannabinoids. J Pharmacol Exp Ther 241: 534–539
Verbene AJM, Taylor DA, Fennessy MR (1980) Withdrawal-like behaviour induced by inhibitors of biogenic amine reuptake in rats treated chronically with Δ9-tetrahydrocannabinol. Psychopharmacology 68: 261–267
Vocci FJ, Petty SK, Dewey WL (1978) Antinociceptive action of butyryl derivatives of guanosine 3′:5′-cyclic monophosphate. J Pharmacol Exp Ther 207: 892–898
Vogel Z, Barg J, Levy R, Saya D, Heldman E, Mechoulam R (1993) Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem 61: 352–355
Volkow ND, Fowler JS (1993) Use of positron emission tomography to study drugs of abuse. In: Nahas GG, Lataur C (eds) Cannabis: physiopathology, epidemiology, detection. CRC Press, Boca Raton, pp 21–43
Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M (1983) Metabolism, disposition, and kinetics of Δ9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 34: 352–363
Walton RP, Martin LF, Keller JH (1937) The relative activity of various purified products obtained from American grown hashish. J Pharmacol Exp Ther 62: 239–251
Ward SJ, Baizman E, Bell M, Childers S, D’Ambra T, Eissenstat M, Estep K, Haycock D,Howlett A, Luttinger D, Miller M (1991) Aminoalkylindoles (AAIs): a new route to the cannabinoid receptor? In: Harris LS (ed) Problems of drug dependence 1990: proceedings of the 52nd annual scientific meeting. US Government Printing Office, Washington DC, pp 425-426
Watanabe N, Moroji T, Tada K, Aoki N (1984) A therapeutic trial of caerulein to a long-term heavy marihuana user with amotivational syndrome. Prog Neuropsychopharmacol Biol Psychiatry 8: 419–421
Wechsler H, Rohman M, Kotch JB, Nelson RK (1984) Alcohol and other drug use and automobile safety: a survey of Boston-area teen-agers. J Sch Health 54: 201–203
Weidenfeld J, Feldman S, Mechoulam R (1994) The effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypotholamo-pituitary-adrenal axis in the rat. Neuroendocrinology 59: 110–112
Weiss JL, Watanabe AM Lemberger L, Tamarkin NR, Cardon PV (1972) Cardiovascular effects of Δ9-tetrahydrocannabinol in man. Clin Pharmacol Ther 13: 671-684
Weissman A (1978) Generalization of the discriminative stimulus properties of Δ9-tetrahydrocannabinol to cannabinoids with therapeutic potential. In: Colpaert FC, Rosecrans JA (eds) Stimulus properties of drugs: ten years of progress. Elsevier/North- Holland Biomedical, Amsterdam, pp 99–122
Welch SP (1993) Blockade of cannabinoid-induced antinociception by nor-binaltorphimine, but not N,N-diallyl-tyrosine -aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. J Pharmacol Exp Ther 256: 633–640
Welch SP, Stevens DL (1992) Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 262: 10–18
Welch SP, Thomas C, Patrick GS (1994) Modulation of cannabinoid-induced antinociception following intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J Pharmacol Exp Ther 272: 310–331
Wenger T, Croix D, Tramu G, Leonardelli J (1992) Effects of Δ9-tetrahydrocannabinol on pregnancy, puberty, and the neuroendocrine system. In: Murphy L, Bartke A (eds) Marijuana/cannabinoids: neurobiology and neurophysiology. CRC Press, Boca Raton, pp 539–560
Westlake TM, Howlett AC, Ali SF, Paule MG, Scallet AC, Slikker W Jr (1991) Chronic exposure to Δ9-tetrahydrocannabinol fails to irreversibly alter brain cannabinoid receptors. Brain Res 544: 145–149
White HL, Tansik RL (1980) Effects of Δ9-tetrahydrocannabinol and cannabidiol on phospholipase and other enzymes regulating arachidonate metabolism. Prostagladins Med 4: 409–411
Wickens AP, Pertwee RG (1993) Δ9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats. Eur J Pharmacol 250:205-208
Williams EG, Himmelsbach CK, Wikler A, Ruble DC, Lloyd BJ Jr (1946) Studies on marihuana and pyrahexyl compound. Public Health Rep 61: 1059–1083
Williams RB, Ng LKY, Lamprecht F, Roth K, Kopin IJ (1973) Δ9-Tetrahydrocannabinol: A hypotensive effect in rats. Psychpharmacology 28:269-274
Wilson RS, May EL (1974) 9-Nor-Δ8-tetrahydrocannabinol, a cannabinoid of metabolic interest. J Med Chem 17:475-476
Wilson RS, May EL (1975) Analgesic properties of the tetrahydrocannabinols, their metabolites, and analogs. J Med Chem 18: 700–703
Wilson RS, May EL (1979) Some 9-hydroxycannabinoid-like compounds. Synthesis and evaluation of analgesic and behavioral properties. J Med Chem 22: 886–888
Yahya MD, Watson RR (1987) Immunomodulation by morphine and marijuana. Life Sci 41: 2503–2510
Yaksh TL (1981) The antinociceptive effects of intrathecally-administered levon-antradol and desacetyllevonantradol in the rat. J Clin Pharmacol 21: 3345–3405
Yaksh TL, Al-Rodhan NRF, Jensen TS (1988) In: Fields HL, Besson JM (eds) Sites of action of opiates in production of analgesia. Elsevier, Amsterdam, pp 371-394 (Progress in brain research, vol 77)
Yebra M, Klein TW, Friedman H (1992) Δ9-tetrahydrocannabinol suppresses concanavalin A induced increase in cytoplasmic free calcium in mouse thymocytes. Life Sci 51:151-160
Zimmerman S, Zimmerman AM, Laurence H (1981) Effect of Δ9-tetrahydrocannabinol on cyclic nucleotides in synchronously dividing Tetrahymena. Can J Biochem 59: 489–493
Zuardi AW, Karniol IG (1983) Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination. Braz J Med Biol Res 16:141–146
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Compton, D.R., Harris, L.S., Lichtman, A.H., Martin, B.R. (1996). Marihuana. In: Schuster, C.R., Kuhar, M.J. (eds) Pharmacological Aspects of Drug Dependence. Handbook of Experimental Pharmacology, vol 118. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60963-3_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-60963-3_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64631-7
Online ISBN: 978-3-642-60963-3
eBook Packages: Springer Book Archive